Prepared: July 27, 2026 Upcoming Earnings: TBD (Q2 2026 — late July / early August 2026) Last Reported: Q1 2026 (April 28, 2026)
Key Takeaway: The setup into Q2 is mixed — consensus is a manageable bar given HLT’s track record of beats, but the Middle East conflict is the single biggest swing factor, with management guiding ~1.5 points of system-wide RevPAR drag in Q2 specifically. The stock has underperformed MAR since last earnings, suggesting the market is pricing in some caution, but peer data from WH’s Q2 print and MAR’s Q1 commentary both point to a resilient U.S. demand backdrop that could allow HLT to beat on the core business even if the Middle East remains a headwind.
Heading into Q2 2026, consensus sits at the high end of management’s own guidance — system-wide RevPAR growth of ~3.4% vs. the guided 2–3% range, and adj. EBITDA of ~$1,039M vs. the $1,015M–$1,035M guidance range — representing a manageable bar given HLT’s eight-quarter consecutive EBITDA beat streak. Management’s tone on the April 28 Q1 call was constructive: full-year RevPAR guidance was raised to 2–3% (from 1–2%) and full-year adj. EPS guidance was lifted to $8.79–$8.91, but management explicitly flagged Q2 as the peak Middle East headwind quarter (~1.5 points of system-wide RevPAR drag), with several one-time timing items also weighing on the Q2 year-over-year comparison. Estimate revisions have been modestly positive since the Q1 print — Q2 adj. EBITDA consensus has drifted up ~$10M from the post-print baseline, suggesting the street is incrementally more constructive, likely reflecting positive peer read-throughs from MAR’s Q1 beat and WH’s Q2 beat. On the stock, HLT has returned only ~+2.3% since the April 28 earnings date vs. MAR +6.9% and SPY +3.8%, underperforming peers and suggesting the market has not fully priced in a beat — creating a potentially attractive setup if Q2 results clear the Middle East overhang. The key wildcard is the pace and trajectory of Middle East recovery: management guided mid-to-high teens RevPAR decline for the region in 2026 with Q2 as the worst quarter, and any sign of faster-than-expected stabilization could be a meaningful positive surprise for both the Q2 print and the full-year outlook.
Key Takeaway: System-wide RevPAR growth is the primary swing factor — consensus at ~3.4% sits at the high end of management’s 2–3% Q2 guidance range, leaving room for a beat if U.S. demand holds and Middle East drag is contained. Adj. EBITDA is the financial scoreboard; HLT has beaten EBITDA consensus in each of the last 8 quarters.
KPI | Q1 2026 Actual | Q2 2025 Actual | Q2 2026 Consensus | YoY Change | Q2 Guidance | Consensus vs. Guidance |
System-wide RevPAR ($) | $105.97 | $121.79 | $124.64 | +2.3% | N/A (growth guided 2–3%) | At high end of range |
System-wide RevPAR Growth (%) | +3.6% | -0.5% | +3.4% | +390bps YoY | 2% to 3% | +40bps above midpoint |
System-wide ADR ($) | $157.14 | $163.78 | $168.21 | +2.7% | N/A | N/A |
System-wide Occupancy (%) | 67.4% | 74.4% | 75.0% | +60bps | N/A | N/A |
Adj. EBITDA ($M) | $901M | $1,008M | $1,039M | +3.1% | $1,015M–$1,035M | +$4M above midpoint |
Diluted EPS — Operating ($) | $2.01 | $2.20 | $2.28 | +3.6% | $2.18–$2.24 | +$0.07 above midpoint |
Revenue ex. Cost Reimbursements ($M) | $1,182M | $1,326M | $1,390M | +4.8% | N/A | N/A |
Franchise & Licensing Fees ($M) | $696M | $745M | $806M | +8.2% | N/A | N/A |
Total Rooms (#) | 1,362,280 | 1,304,880 | 1,388,380 | +6.4% | 6–7% NUG | In line |
Source: Visible Alpha consensus and actuals. All consensus figures as of July 27, 2026. HLT has beaten adj. EBITDA consensus in each of the last 8 quarters, with beats ranging from $8M to $47M. Franchise & licensing fees are a key non-RevPAR revenue driver that has consistently outperformed.
Quarter | Reported | Consensus | Surprise | Result |
Q2 2024 | +3.5% | +3.2% | +30bps | Beat |
Q3 2024 | +1.4% | +1.9% | -50bps | Miss |
Q4 2024 | +3.5% | +2.0% | +150bps | Beat |
Q1 2025 | +2.5% | +3.0% | -50bps | Miss |
Q2 2025 | -0.5% | +0.0% | -50bps | Miss |
Q3 2025 | -1.1% | -0.8% | -30bps | Miss |
Q4 2025 | +0.5% | +0.3% | +20bps | Beat |
Q1 2026 | +3.6% | +2.4% | +120bps | Beat |
Quarter | Reported ($M) | Consensus ($M) | Surprise ($M) | Result |
Q2 2024 | $917M | $902M | +$15M | Beat |
Q3 2024 | $904M | $885M | +$19M | Beat |
Q4 2024 | $858M | $831M | +$27M | Beat |
Q1 2025 | $795M | $781M | +$14M | Beat |
Q2 2025 | $1,008M | $961M | +$47M | Beat |
Q3 2025 | $976M | $950M | +$26M | Beat |
Q4 2025 | $946M | $924M | +$22M | Beat |
Q1 2026 | $901M | $893M | +$8M | Beat |
HLT has beaten adj. EBITDA consensus in all 8 of the last 8 quarters, with beats ranging from $8M to $47M. RevPAR growth has been more mixed (5 beats, 3 misses), with misses concentrated in the soft demand period of mid-2025. The consistent EBITDA beat pattern reflects HLT’s ability to drive non-RevPAR fee growth and cost discipline even when RevPAR disappoints.
Key Takeaway: Management raised full-year RevPAR and EPS guidance on the Q1 call, but Q2 is explicitly flagged as the peak Middle East headwind quarter. No post-earnings guidance revisions have been issued, so the April 28 Q1 earnings call remains the sole baseline.
Metric | Initial Guidance (Q1 2026 Call, Apr 28) | Revised Guidance | Current Consensus | Note |
Q2 System-wide RevPAR Growth | 2% to 3% | — | +3.4% | Consensus at high end; Middle East ~1.5pt drag flagged as peak Q2 headwind |
Q2 Adj. EBITDA | $1,015M–$1,035M | — | $1,039M | Consensus $4M above midpoint; one-time timing items flagged for Q2 |
Q2 Diluted EPS (Operating) | $2.18–$2.24 | — | $2.28 | Consensus $0.07 above midpoint; buyback optionality not in guidance |
FY 2026 System-wide RevPAR Growth | 2% to 3% | — | +2.8% | Raised from prior 1–2% range; Middle East 0.5–1pt full-year drag assumed |
FY 2026 Adj. EBITDA | $4,020M–$4,060M | — | $4,054M | Consensus near high end of range; non-RevPAR fee growth a key upside driver |
FY 2026 Diluted EPS (Operating) | $8.79–$8.91 | — | $8.98 | Consensus above guidance range; reflects buyback optionality not embedded in guidance |
Net Unit Growth (FY 2026) | 6% to 7% | — | ~6.4% | Record pipeline of 527,000 rooms; construction starts up 20%+ for the year |
Key Takeaway: Estimates have drifted modestly higher since the Q1 print — Q2 adj. EBITDA consensus is up ~$10M from the post-print baseline, and FY 2026 adj. EBITDA is essentially flat. The gap between consensus and guidance midpoints is small, suggesting the street is not pricing in a large beat but also not pricing in a miss. FY EPS consensus sitting above the guidance range reflects buyback optionality not embedded in guidance.
KPI (Period) | Estimate (May 3, 2026 — ~5 days post Q1 print) | Current Consensus | Estimate Δ (%) | Initial Guidance (Q1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
System-wide RevPAR Growth — Q2 2026 | +2.3% | +3.4% | +110bps | 2%–3% | Unchanged | — | +40bps above midpoint |
Adj. EBITDA — Q2 2026 | $1,029M | $1,039M | +1.0% | $1,015M–$1,035M | Unchanged | — | +$4M above midpoint |
Diluted EPS (Op.) — Q2 2026 | $2.24 | $2.28 | +1.8% | $2.18–$2.24 | Unchanged | — | +$0.07 above midpoint |
Adj. EBITDA — FY 2026 | $4,043M | $4,054M | +0.3% | $4,020M–$4,060M | Unchanged | — | Near high end of range |
Diluted EPS (Op.) — FY 2026 | $9.02 | $8.98 | -0.4% | $8.79–$8.91 | Unchanged | — | Above guidance range |
Source: Visible Alpha. May 3, 2026 as-of date represents the clean post-print baseline ~5 trading days after the April 28 Q1 earnings release. The modest upward drift in Q2 EBITDA estimates (+$10M) since the post-print baseline likely reflects positive peer read-throughs from MAR’s Q1 beat and WH’s Q2 beat. FY EPS consensus sitting above the guidance range reflects buyback optionality not embedded in guidance (HLT targets ~$3.5B in total capital returns for 2026).
Key Takeaway: HLT has underperformed both MAR (+6.9%) and the S&P 500 (+3.8%) since the Q1 earnings date (April 28, 2026), returning only +2.3% on an indexed basis through July 28. The underperformance is likely driven by the Middle East overhang and the initial market disappointment that the FY EPS guidance midpoint came in below sell-side consensus — creating a potentially attractive setup if Q2 clears the overhang.
HLT vs. MAR (peer) vs. S&P 500 (SPY) — Indexed to 100 at April 28, 2026 (Q1 2026 Earnings Date). Peer benchmark: MAR (Marriott International). Event markers: Leadership Reshuffle (May 5), $1B Senior Notes (May 11), Incentive Plan Approved (May 18). Source: Yahoo Finance.
Key Takeaway: The most material post-earnings development is the leadership reshuffle (May 5) — the planned retirement of President Chris Silcock and the external search for a new CTO signal meaningful organizational change heading into a critical demand inflection period. The $1B senior notes issuance is routine balance-sheet management.
Key Takeaway: Peer commentary from the last 60 days is broadly constructive for HLT’s Q2 print — U.S. demand is accelerating, group is strong, and leisure trends are durable. The Middle East remains a shared headwind across the sector, but peers confirm Q2 is the peak impact quarter, consistent with HLT’s guidance. Note: this section covers only forward-looking commentary about Q2 2026 and beyond — backward-looking commentary about prior quarter results is excluded.
Most directly relevant — WH just reported Q2 2026 results, providing the most current read on the demand environment heading into HLT’s print.
Reported Q1 2026 results; forward-looking commentary about Q2 and full year is relevant for HLT’s setup.
Forward-looking strategic commentary; relevant for industry demand outlook and premium segment read-through.
Reported Q1 2026; forward-looking commentary about Q2 and full year is relevant for HLT’s economy and mid-scale segment read-through.
Key Takeaway: All transactions since the Q1 earnings date are director stock awards (grants), not open-market purchases or sales. No open-market buys or sells have been filed by any executive officer or director — the absence of discretionary insider buying is neutral, not a negative signal given the award-only nature of all activity.
Name | Title | Transaction Type | Shares | Effective Date | Disclosed Date | Note |
Charlene T. Begley | Director | Stock Award (Grant) | 742 | May 14, 2026 | May 18, 2026 | Routine director equity compensation |
Chris Carr | Director | Stock Award (Grant) | 742 | May 14, 2026 | May 18, 2026 | Routine director equity compensation |
Jonathan Gray | Director | Stock Award (Grant) | 742 + 104 | May 14 & May 1, 2026 | May 18 & May 5, 2026 | Routine director equity compensation (two grants) |
Melanie Healey | Director | Stock Award (Grant) | 742 | May 14, 2026 | May 18, 2026 | Routine director equity compensation |
Raymond E. Mabus | Director | Stock Award (Grant) | 742 | May 14, 2026 | May 18, 2026 | Routine director equity compensation |
Marissa A. Mayer | Director | Stock Award (Grant) | 742 + 115 | May 14 & May 1, 2026 | May 18 & May 5, 2026 | Routine director equity compensation (two grants) |
Elizabeth A. Smith | Director | Stock Award (Grant) | 742 + 145 | May 14 & May 1, 2026 | May 18 & May 5, 2026 | Routine director equity compensation (two grants) |
Douglas M. Steenland | Director | Stock Award (Grant) | 742 | May 14, 2026 | May 18, 2026 | Routine director equity compensation |
Multiple Directors (8) | Directors | Stock Award (Grant) | ~5–9 shares each | June 30, 2026 | July 1, 2026 | Small fractional quarterly dividend reinvestment awards |
Source: SEC Form 4 filings. All transactions are Form 4 code “A” (awards/grants), not open-market purchases (code “P”) or sales (code “S”). No executive officers (CEO, CFO, COO) have filed any Form 4 transactions in the period. The absence of open-market buying by executives is neutral given the award-only nature of all activity.